Russian prostate cancer care under the microscope: no new drug, just data

NCT ID NCT07146113

Terminated Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcomes. Because it is purely observational, it will not change anyone's treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DE NOVO METASTATIC HORMONE SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Research Site

Arkhangelsk, Russia
Research Site

Barnaul, Russia
Research Site

Chelyabinsk, Russia
Research Site

Irkutsk, Russia
Research Site

Krasnodar, Russia
Research Site

Krasnoyarsk, Russia
Research Site

Moscow, Russia
Research Site

Nizhny Novgorod, Russia
Research Site

Obninsk, Russia
Research Site

Omsk, Russia
Research Site

Saint Petersburg, Russia
Research Site

Saransk, Russia
Research Site

Tomsk, Russia
Research Site

Tyumen, Russia
Research Site

Ufa, Russia
Research Site

Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.